<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661034</url>
  </required_header>
  <id_info>
    <org_study_id>CA-0004</org_study_id>
    <nct_id>NCT03661034</nct_id>
  </id_info>
  <brief_title>Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)</brief_title>
  <official_title>Multi-Center Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognito Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cognito Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to
      assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients
      with cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled in two Cohorts (N=10 each, enrolled sequentially), and each will
      assess two different dose levels (randomly assigned). Based on initial outcomes in Cohort 1
      at Interim Analysis, the doses for Cohort 2 will be escalated or decreased. Subjects will
      participate in 1 year (48 weeks) of daily therapy dose using the non-invasive,
      non-significant risk sensory stimulation medical device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, four-arm prospective dose-adjusting study (2 cohorts sequentially enrolled, each with 2 randomly assigned dose levels)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Amyloid Positron Emission Tomography (PET) Scan</measure>
    <time_frame>PET Imaging at Baseline, 6 weeks and every 3 months throughout therapy (0, 1.5, 3, 6, 9 and 12 month)</time_frame>
    <description>Movement of amyloid, as measured qualitatively and quantitatively in Amyloid PET Imaging at 0, 1.5, 3, 6, 9 and 12 months following assigned regimen of sensory stimulation treatment sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Composite adverse events to be assessed at Interim Analysis (at any point in partial study completion), and final analysis (at 6 and 12 months time points).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Baseline, 3, 6, 9 and 12 months</time_frame>
    <description>A scale used to assess cognition; This scale consists of 14 questions assessed resulting in a score from 0 to 90, where a higher score indicates more cognitive disruption.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer Disease, Early Onset</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Alzheimer Dementia</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Memory Disorders</condition>
  <condition>Memory Loss</condition>
  <condition>Memory Impairment</condition>
  <condition>Memory Disorders, Age Related</condition>
  <condition>Alzheimer Disease, Late Onset</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Dementia, Mild</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaSense Stimulation System (non-invasive, non-significant risk)</intervention_name>
    <description>Non-invasive, non-significant risk audio-visual sensory stimulation device</description>
    <arm_group_label>Cohort 1, Arm A</arm_group_label>
    <arm_group_label>Cohort 1, Arm B</arm_group_label>
    <arm_group_label>Cohort 2, Arm C</arm_group_label>
    <arm_group_label>Cohort 2, Arm D</arm_group_label>
    <other_name>FG-0003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 50 Years Old

          -  MMSE 24 - 30

          -  Prodromal Alzheimer's Disease (AD), AD or Mild Cognitive Impairment (MCI) due to AD

          -  Participation of a caregiver / care partner

          -  Amyloid Positive PET Scan

        Exclusion Criteria:

          -  Profound hearing or visual impairment

          -  Seizure Disorder

          -  Use of memantine (Namenda or Namzaric)

          -  Implantable devices (non-MR compatible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan R Hempel</last_name>
    <role>Study Chair</role>
    <affiliation>Cognito Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evan R Hempel</last_name>
    <phone>857-201-5088</phone>
    <email>info@cognitotx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linh Huynh, PharmD</last_name>
      <phone>617-699-6927</phone>
      <email>linh@bostonmemory.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Memory Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Late Onset Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

